Jazz Pharmaceuticals PLC (JAZZ) Receives $192.28 Average PT from Analysts

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) has been assigned a consensus rating of “Buy” from the twenty-two research firms that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and sixteen have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $193.56.

JAZZ has been the subject of a number of research reports. BidaskClub upgraded shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 21st. B. Riley raised their price objective on shares of Jazz Pharmaceuticals from $211.00 to $219.00 and gave the company a “buy” rating in a report on Tuesday, June 26th. Wells Fargo & Co reiterated a “buy” rating on shares of Jazz Pharmaceuticals in a report on Monday, July 2nd. Citigroup raised their price objective on shares of Jazz Pharmaceuticals from $162.00 to $205.00 and gave the company a “buy” rating in a report on Tuesday, July 10th. Finally, Zacks Investment Research lowered shares of Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 10th.

Shares of JAZZ stock traded down $0.01 on Friday, reaching $155.99. The company had a trading volume of 417,500 shares, compared to its average volume of 480,794. The stock has a market capitalization of $9.60 billion, a P/E ratio of 16.32, a price-to-earnings-growth ratio of 0.86 and a beta of 1.04. The company has a current ratio of 3.76, a quick ratio of 3.62 and a debt-to-equity ratio of 0.54. Jazz Pharmaceuticals has a one year low of $128.58 and a one year high of $184.00.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported $3.49 EPS for the quarter, topping analysts’ consensus estimates of $3.23 by $0.26. The firm had revenue of $500.48 million during the quarter, compared to analysts’ expectations of $469.85 million. Jazz Pharmaceuticals had a net margin of 24.20% and a return on equity of 25.47%. As a group, equities analysts predict that Jazz Pharmaceuticals will post 11.71 EPS for the current fiscal year.

In other Jazz Pharmaceuticals news, CFO Matthew P. Young sold 700 shares of the firm’s stock in a transaction that occurred on Monday, October 15th. The shares were sold at an average price of $158.08, for a total transaction of $110,656.00. Following the completion of the transaction, the chief financial officer now owns 32,768 shares in the company, valued at approximately $5,179,965.44. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Bruce C. Cozadd sold 1,600 shares of the firm’s stock in a transaction that occurred on Wednesday, August 1st. The stock was sold at an average price of $173.90, for a total transaction of $278,240.00. Following the transaction, the chief executive officer now owns 282,515 shares of the company’s stock, valued at approximately $49,129,358.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 34,978 shares of company stock valued at $6,030,128. Company insiders own 3.90% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in JAZZ. Financial Gravity Wealth Inc. bought a new position in Jazz Pharmaceuticals during the 1st quarter worth approximately $192,000. Northern Trust Corp grew its position in shares of Jazz Pharmaceuticals by 5.6% during the 1st quarter. Northern Trust Corp now owns 231,817 shares of the specialty pharmaceutical company’s stock worth $35,001,000 after buying an additional 12,252 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Jazz Pharmaceuticals by 14.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 291,850 shares of the specialty pharmaceutical company’s stock worth $44,066,000 after buying an additional 37,486 shares during the period. Russell Investments Group Ltd. grew its position in shares of Jazz Pharmaceuticals by 113.0% during the 1st quarter. Russell Investments Group Ltd. now owns 32,015 shares of the specialty pharmaceutical company’s stock worth $4,803,000 after buying an additional 16,983 shares during the period. Finally, Sei Investments Co. grew its position in shares of Jazz Pharmaceuticals by 75.9% during the 1st quarter. Sei Investments Co. now owns 9,698 shares of the specialty pharmaceutical company’s stock worth $1,464,000 after buying an additional 4,185 shares during the period. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Featured Article: What Is An Exchange-Traded Fund (ETF)?

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply